IE51070B1 - Pharmaceutical formulations comprising cisplatatin solutions - Google Patents
Pharmaceutical formulations comprising cisplatatin solutionsInfo
- Publication number
- IE51070B1 IE51070B1 IE715/81A IE71581A IE51070B1 IE 51070 B1 IE51070 B1 IE 51070B1 IE 715/81 A IE715/81 A IE 715/81A IE 71581 A IE71581 A IE 71581A IE 51070 B1 IE51070 B1 IE 51070B1
- Authority
- IE
- Ireland
- Prior art keywords
- cisplatin
- solution
- polyethylene glycol
- solutions
- molecular weight
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 147
- 229960004316 cisplatin Drugs 0.000 claims abstract description 144
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 20
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 10
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 66
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 42
- 239000011780 sodium chloride Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 142
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 57
- 238000004809 thin layer chromatography Methods 0.000 description 39
- 238000003860 storage Methods 0.000 description 35
- 229910052697 platinum Inorganic materials 0.000 description 29
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 25
- 239000008213 purified water Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 12
- 229930195725 Mannitol Natural products 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000000594 mannitol Substances 0.000 description 12
- 235000010355 mannitol Nutrition 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 10
- 229910052782 aluminium Inorganic materials 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 238000013112 stability test Methods 0.000 description 9
- 239000008227 sterile water for injection Substances 0.000 description 9
- 239000004809 Teflon Substances 0.000 description 8
- 229920006362 Teflon® Polymers 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000010268 HPLC based assay Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229920005549 butyl rubber Polymers 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- -1 sodium chloride Chemical compound 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 231100000766 Possible carcinogen Toxicity 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910019029 PtCl4 Inorganic materials 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- RXNBDWQDJKUHNH-UHFFFAOYSA-L azane;cobalt(2+);dithiocyanate Chemical compound N.[Co+2].[S-]C#N.[S-]C#N RXNBDWQDJKUHNH-UHFFFAOYSA-L 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229910001504 inorganic chloride Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- FBEIPJNQGITEBL-UHFFFAOYSA-J tetrachloroplatinum Chemical compound Cl[Pt](Cl)(Cl)Cl FBEIPJNQGITEBL-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13537380A | 1980-03-31 | 1980-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE810715L IE810715L (en) | 1981-09-30 |
| IE51070B1 true IE51070B1 (en) | 1986-09-17 |
Family
ID=22467813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE715/81A IE51070B1 (en) | 1980-03-31 | 1981-03-30 | Pharmaceutical formulations comprising cisplatatin solutions |
Country Status (30)
| Country | Link |
|---|---|
| JP (1) | JPS56152415A (it) |
| KR (1) | KR860000841B1 (it) |
| AR (1) | AR225500A1 (it) |
| AT (1) | AT370996B (it) |
| AU (1) | AU541056B2 (it) |
| BE (1) | BE888209A (it) |
| CA (1) | CA1162479A (it) |
| CH (1) | CH647481A5 (it) |
| CS (1) | CS246051B2 (it) |
| DD (1) | DD157762A5 (it) |
| DE (1) | DE3112272A1 (it) |
| DK (1) | DK158564C (it) |
| ES (1) | ES8206545A1 (it) |
| FI (1) | FI70670C (it) |
| FR (1) | FR2480605A1 (it) |
| GB (1) | GB2074028B (it) |
| GR (1) | GR72769B (it) |
| HU (1) | HU183379B (it) |
| IE (1) | IE51070B1 (it) |
| IL (1) | IL62517A (it) |
| IT (1) | IT1170838B (it) |
| LU (1) | LU83270A1 (it) |
| NL (1) | NL8101531A (it) |
| NO (1) | NO156675C (it) |
| NZ (1) | NZ196519A (it) |
| PH (1) | PH17152A (it) |
| PT (1) | PT72774B (it) |
| SE (1) | SE455045B (it) |
| SU (1) | SU1056893A3 (it) |
| ZA (1) | ZA812084B (it) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
| NL8303657A (nl) * | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
| FI895340A0 (fi) * | 1988-11-14 | 1989-11-09 | Bristol Myers Squibb Co | Hypertonisk cisplatin-loesning. |
| DK0929293T3 (da) * | 1996-08-23 | 2004-02-02 | Sequus Pharm Inc | Liposomer indeholdende en cisplatinforbindelse |
| AUPQ641100A0 (en) | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
| JP4445304B2 (ja) | 2004-03-26 | 2010-04-07 | オンキヨー株式会社 | スイッチングアンプ |
| US8852566B2 (en) * | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
| JP7464995B2 (ja) | 2018-03-29 | 2024-04-10 | プロジェクト ファーマシューティクス ゲーエムベーハー | 液体薬学的製剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177263A (en) * | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
| CA1119954A (en) * | 1978-05-30 | 1982-03-16 | Edmund S. Granatek | Aqueous solution of cisplatin |
-
1981
- 1981-03-06 AU AU68166/81A patent/AU541056B2/en not_active Ceased
- 1981-03-06 CA CA000372499A patent/CA1162479A/en not_active Expired
- 1981-03-17 NZ NZ196519A patent/NZ196519A/xx unknown
- 1981-03-24 FR FR8105848A patent/FR2480605A1/fr active Granted
- 1981-03-24 IT IT48090/81A patent/IT1170838B/it active
- 1981-03-25 CH CH2023/81A patent/CH647481A5/fr not_active IP Right Cessation
- 1981-03-26 FI FI810934A patent/FI70670C/fi not_active IP Right Cessation
- 1981-03-26 GR GR64497A patent/GR72769B/el unknown
- 1981-03-27 PH PH25435A patent/PH17152A/en unknown
- 1981-03-27 ZA ZA00812084A patent/ZA812084B/xx unknown
- 1981-03-27 NL NL8101531A patent/NL8101531A/nl not_active Application Discontinuation
- 1981-03-27 DE DE19813112272 patent/DE3112272A1/de active Granted
- 1981-03-27 SE SE8101990A patent/SE455045B/sv not_active IP Right Cessation
- 1981-03-28 KR KR1019810001029A patent/KR860000841B1/ko active
- 1981-03-30 SU SU813265697A patent/SU1056893A3/ru active
- 1981-03-30 HU HU81811A patent/HU183379B/hu not_active IP Right Cessation
- 1981-03-30 GB GB8109926A patent/GB2074028B/en not_active Expired
- 1981-03-30 IE IE715/81A patent/IE51070B1/en not_active IP Right Cessation
- 1981-03-30 DK DK144281A patent/DK158564C/da not_active IP Right Cessation
- 1981-03-30 NO NO811081A patent/NO156675C/no unknown
- 1981-03-30 PT PT72774A patent/PT72774B/pt not_active IP Right Cessation
- 1981-03-30 IL IL62517A patent/IL62517A/xx unknown
- 1981-03-30 AR AR284799A patent/AR225500A1/es active
- 1981-03-30 ES ES500869A patent/ES8206545A1/es not_active Expired
- 1981-03-30 JP JP4569081A patent/JPS56152415A/ja active Granted
- 1981-03-31 AT AT0150481A patent/AT370996B/de not_active IP Right Cessation
- 1981-03-31 CS CS812390A patent/CS246051B2/cs unknown
- 1981-03-31 BE BE0/204323A patent/BE888209A/fr not_active IP Right Cessation
- 1981-03-31 LU LU83270A patent/LU83270A1/fr unknown
- 1981-03-31 DD DD81228776A patent/DD157762A5/de not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4451447A (en) | Pharmaceutical formulations | |
| US4322391A (en) | Process for the preparation of microcrystalline cisplatin | |
| US4310515A (en) | Pharmaceutical compositions of cisplatin | |
| JP3547755B2 (ja) | オキサリプラティヌムの医薬的に安定な製剤 | |
| FI78236B (fi) | Foerfarande foer framstaellning av en frystorkad doseringsenhet av cis-platina (ii) diamindiklorid. | |
| KR100351713B1 (ko) | 백금(ii) 항종양제의 안정용액 | |
| IE51070B1 (en) | Pharmaceutical formulations comprising cisplatatin solutions | |
| Landi-Librandi et al. | Study of quercetin-loaded liposomes as potential drug carriers: in vitro evaluation of human complement activation | |
| CA1119954A (en) | Aqueous solution of cisplatin | |
| Orbell et al. | Preparation and structure of cis-chlorodiammine (N2, N2-dimethyl-9-methylguanine) platinum (II) hexafluorophosphate. A model for the intermediate in the proposed crosslinking mode of action of platinum (II) antitumor agents | |
| US4946689A (en) | Concentrated, stabilized cis-diamminedinitratoplatinum solutions for conversion to cisplatin | |
| Hem et al. | Evaluation of antacid suspensions containing aluminum hydroxide and magnesium hydroxide | |
| Shamsuddin et al. | Synthesis and Crystal Structure of a New Antitumor Agent:[Pt (cis-1, 4-Diaminocyclohexane)(1, 1-Cyclobutanedicarboxylate)] | |
| Lien et al. | The mechanism of cobalamin binding to hog intrinsic factor | |
| AU623632B2 (en) | A solution of carboplatin | |
| FI72302B (fi) | Foerfarande foer framstaellning av stabilt mikrokristallint ciplatin | |
| Akaboshi et al. | Relationship between Cell‐killing Efficiency and Number of Platinum Atoms Binding to DNA, RNA, and Protein Molecules in HeLa Cells Treated with cis‐Diamine (glycolato) platinum (II) | |
| RU2157813C2 (ru) | Средство, обладающее лейкопоэзстимулирующим, иммуномодулирующим и антибактериальным действием | |
| CN112220795A (zh) | 维生素c-吉西他滨,其制备,抗肿瘤活性和应用 | |
| Przybylska et al. | Crystallization and preliminary crystallographic data for oncomodulin | |
| CA2537610A1 (en) | Pharmaceutical composition, method of manufacturing and therapeutic use thereof | |
| WO1998035972A1 (es) | Complejo de platino con actividad antineoplasica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |